ArticleEndocrine connections2018
Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism.
Article in Endocrine connections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The differentiation between primary aldosteronism and essential hypertension in left ventricular remodeling before and after treatment: a follow-up study with quantitative stress cardiac magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2025Article
- Multimodality Imaging in Aldosterone-Induced Cardiomyopathy: Early Detection and Prognostic Implications.Diagnostics (Basel, Switzerland) · 2025Review
- Left ventricle remodeling by CMR in treated patients with primary aldosteronism and primary systemic arterial hypertension.PloS one · 2024Article
- Strain Imaging for the Early Detection of Cardiac Remodeling and Dysfunction in Primary Aldosteronism.Diagnostics (Basel, Switzerland) · 2022Review
- Left Ventricular Remodeling in Patients with Primary Aldosteronism: A Prospective Cardiac Magnetic Resonance Imaging Study.Korean journal of radiology · 2021Article
- Left ventricular remodeling and dysfunction in primary aldosteronism.Journal of human hypertension · 2021Review
- CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients.Frontiers in endocrinology · 2021Article
- Aldosterone-induced cardiac damage in primary aldosteronism depends on its subtypes.Endocrine connections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary aldosteronism (PA) is associated with increased cardiovascular morbidity, presumably due to left ventricular (LV) hypertrophy and fibrosis. However, the degree of fibrosis has not been extensively studied. Cardiac magnetic resonance imaging (CMR) contrast enhancement and novel sensitive T1 mapping to estimate increased extracellular volume (ECV) are available to measure the extent of fibrosis.
objectivesTo assess LV mass and fibrosis before and after treatment of PA using CMR with contrast enhancement and T1 mapping.
methodsFifteen patients with newly diagnosed PA (PA1) and 24 age- and sex-matched healthy subjects (HS) were studied by CMR with contrast enhancement. Repeated imaging with a new scanner with T1 mapping was performed in 14 of the PA1 and 20 of the HS median 18 months after specific PA treatment and in additional 16 newly diagnosed PA patients (PA2).
resultsPA1 had higher baseline LV mass index than HS (69 (53-91) vs 51 (40-72) g/m
conclusionSpecific treatment rapidly reduced LV mass in PA. Increased myocardial fibrosis was not found and may not represent a common clinical problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.